Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Giorgio V ScagliottiRamaswamy Govindan

Abstract

Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. The primary end point was OS. Key secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. In all, 960 patients were randomly assigned, and baseline characteristics were balanced. Median OS was 9.0 months for sunitinib plus erlotinib versus 8.5 months for erlotinib alone (hazard ratio [HR], 0.922; 95% CI, 0.797 to 1.067; one-sided stratified log-rank P = .1388). Median PFS was 3.6 months versus 2.0 months (HR, 0.807; 95% CI, 0.6...Continue Reading

Associated Clinical Trials

References

Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 25, 2007·Health and Quality of Life Outcomes·A Simon PickardDavid Cella
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiGiorgio V Scagliotti
Apr 1, 2009·Nature Reviews. Clinical Oncology·Francesco TorinoGiampietro Gasparini
Nov 12, 2009·Journal of the National Cancer Institute·Kristine R Broglio, Donald A Berry
Mar 2, 2010·Thyroid : Official Journal of the American Thyroid Association·Jerome M Hershman, Llanyee Liwanpo

❮ Previous
Next ❯

Citations

Oct 12, 2011·Investigational New Drugs·George R Blumenschein
Jan 30, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Majem, C Pallarès
Nov 10, 2013·Nature Medicine·Curtis R Chong, Pasi A Jänne
Jun 22, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J M GroenG R Blumenschein
Mar 1, 2014·Drugs·Bilal PiperdiRoman Perez-Soler
Jan 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K KubotaK Park
Jul 9, 2014·The Journal of Clinical Investigation·Miguel Manuel MurilloJulian Downward
Oct 19, 2014·Journal of the National Cancer Institute·Philip WongDian Wang
Feb 18, 2016·Future Oncology·Konstantinos Koutsoukos, Giannis Mountzios
Feb 24, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sun Min LimJoo-Hang Kim
Aug 15, 2014·Expert Review of Clinical Pharmacology·Martin ReckNiels Reinmuth
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Erika RijavecFrancesco Grossi
Mar 5, 2013·Expert Opinion on Investigational Drugs·Judy W King, Siow-Ming Lee
Jun 13, 2015·Expert Opinion on Investigational Drugs·Sara PilottoEmilio Bria
Dec 4, 2012·Expert Opinion on Biological Therapy·Joel W Neal, Heather A Wakelee
Jan 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rebecca S HeistUNKNOWN Alliance for Clinical Trials in Oncology
Apr 24, 2012·Hematology/oncology Clinics of North America·Anish ThomasGiuseppe Giaccone
Mar 13, 2012·Revue des maladies respiratoires·C Clément-DuchêneY Martinet
Aug 29, 2013·British Journal of Clinical Pharmacology·Roberto IacovelliEnrico Cortesi
Jun 9, 2014·The Journal of Thoracic and Cardiovascular Surgery·Cherry Ballard-CroftJoseph B Zwischenberger
May 8, 2015·Current Oncology Reports·Liza C Villaruz, Mark A Socinski
Nov 7, 2014·Journal of Cancer Research and Clinical Oncology·Shaodong HongLi Zhang
Apr 8, 2016·Expert Opinion on Investigational Drugs·Luisa CarbogninEmilio Bria
Nov 15, 2014·Future Oncology·Giovenzio GenestretiAlba A Brandes
Nov 4, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·T T ZhangG B Chen
Jun 18, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Radj GervaisRay D Page
Sep 10, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jared M WeissThomas E Stinchcombe
Aug 11, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Alan SandlerDavid H Johnson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
David R SpigelJohn D Hainsworth
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ronald B NataleG Goss
The New England Journal of Medicine
Frances A ShepherdNational Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Giorgio V ScagliottiNasser Hanna
© 2021 Meta ULC. All rights reserved